Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07254754 | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma(LATE-R-GEL-23) | recruiting | Phase 2 | 45 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT04484012 | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER |
| 1 |
| Nov 26, 2025 |
| clinicaltrials |
| NCT04785989 | In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia) | recruiting | — | 16 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies(LONGSAFE) | recruiting | N/A | 40 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07084662 | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma | recruiting | Phase 2 / Phase 3 | 80 | Sun Yat-sen UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | recruiting | Phase 2 | 79 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07139509 | Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma(UCAR-T_MM-XA) | recruiting | Phase 1 | 18 | Xi'an No.3 HospitalOTHER_GOV | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07249073 | CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07236021 | e-Motion : Promoting Emotion Regulation in Chronic Cancer | recruiting | N/A | 30 | Université Libre de BruxellesOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03717844 | Registry for Adults With Plasma Cell Disorders (PCD's) | recruiting | — | 2,000 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04795882 | A New Study Evaluating the Activity of Modular CAR T for mYeloma(MCARTY) | recruiting | Phase 1 | 27 | University College, LondonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06449885 | A Cohort Study in Newly Diagnosed MZL | recruiting | — | 2,500 | Fudan UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07180992 | Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma(MONOMM) | recruiting | — | 25 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07188077 | Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | — | 20 | Ting YANGOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07233720 | Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma | recruiting | — | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02641145 | Molecular Imaging of Primary Amyloid Cardiomyopathy(MICA) | recruiting | N/A | 171 | Brigham and Women's HospitalOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06550141 | Emapalumab Prevention of CAR-T Cell Associated Toxicities | recruiting | Phase 2 | 28 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06055894 | A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT03375619 | Long-term Follow-up Study of Patients Receiving CAR-T Cells | recruiting | — | 500 | Medical College of WisconsinOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04114084 | Sleep Apnea in Patients With MGUS and MM | recruiting | — | 200 | Michael TomassonOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06916767 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | recruiting | Phase 1 | 18 | Paolo Caimi, MDOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05943496 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | recruiting | Phase 1 | 27 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT07025005 | Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)(VRd MM Fibrate) | recruiting | Phase 4 | 44 | Tanta UniversityOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06569680 | Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | Izidore Lossos, MDOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05363111 | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT06796998 | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | recruiting | Phase 2 | 25 | Izidore Lossos, MDOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | recruiting | Phase 2 | 227 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 20, 2025 | clinicaltrials |
| NCT00626496 | Family Study of Lymphoproliferative Disorders | recruiting | — | 3,000 | Mayo ClinicOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06520098 | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(Benefit VA) | recruiting | Phase 2 | 100 | VA Office of Research and DevelopmentFED | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03016806 | Umbilical Cord Blood Transplantation From Unrelated Donors | recruiting | — | 30 | University of RochesterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05940272 | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers | recruiting | N/A | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | recruiting | Phase 2 | 169 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07205523 | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)(HALO-SCT) | recruiting | — | 1,000 | Yigeng Cao,MD,PhDOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05932680 | Limited-duration Teclistamab | recruiting | Phase 2 | 75 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma(CaMMouflage) | recruiting | Phase 1 | 50 | Caribou Biosciences, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 28, 2025source: clinicaltrials